NCNA

NuCana plc

Healthcare · Biotechnology

$1.29Sep 28, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Strong evidence · 3 sources

Why it matters

NuCana plc execution reads as mixed on proprietary earnings and initiative evidence.

Why it matters: Re-appointment of Ernst & Young LLP as auditors (Q2 FY2026).

ExecutionMixed
CapitalReinvesting

2 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Re-appointment of Ernst & Young LLP as auditors (Q2 FY2026)
  • Share Sub-division and Redesignation (Q2 FY2026)

Pipeline evidence · 0d ago

NCNA's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on NCNA.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest Intelligence

Updated

What happened recently for NuCana plc (NCNA) — events, not interpretation.

Event
Last session September 28, 2026 at $1.29.
Source
Market data

Research & analysis only — not investment advice.

Building company intelligence…

NuCana plc (NCNA)

Healthcare · Biotechnology

Investment Snapshot above is the primary AlphaOS analysis for NuCana plc — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Industry:
Biotechnology
Market cap:
$26.84B

NCNA earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow NuCana plc through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.